Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion—With an application to the design of a clinical trial in acute myeloid leukemia
Kaspar Rufibach, Dominik Heinzmann, Annabelle Monnet · Pharmaceutical Statistics · 2019
For a trial with primary endpoint overall survival for a molecule with curative potential, statistical methods that rely on the proportional hazards assumption may underestimate the power and the time to final analysis. We show how a cure proportion model can be used to get the necessary number of events and appropriate timing via simulation. If phase 1 results for the new drug are exceptional and/or the medical need in the target population is high, a phase 3 trial might be initiated after phase 1. Building in a futility interim analysis into such a pivotal trial may mitigate the uncertainty of moving directly to phase 3. However, if cure is possible, overall survival might not be mature enough at the interim to support a futility decision. We propose to base this decision on an intermediate endpoint that is sufficiently associated with survival. Planning for such an interim can be interpreted as making a randomized phase 2 trial a part of the pivotal trial: If stopped at the interim, the trial data would be analyzed, and a decision on a subsequent phase 3 trial would be made. If the trial continues at the interim, then the phase 3 trial is already underway. To select a futility boundary, a mechanistic simulation model that connects the intermediate endpoint and survival is proposed. We illustrate how this approach was used to design a pivotal randomized trial in acute myeloid leukemia and discuss historical data that informed the simulation model and operational challenges when implementing it.
Cited by 3 works. doi:10.1002/pst.1969 Open-access PDF
Authors
References
- Maximum Likelihood Estimates of the Proportion of Patients Cured by Cancer Therapy
- Sample-Size Formula for the Proportional-Hazards Regression Model
- The Catalogue of Somatic Mutations in Cancer (COSMIC)
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
- Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
- Analyzing survival curves at a fixed point in time
- Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
- Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work
- MDM2 inhibitors for cancer therapy
- A Nonparametric Mixture Model for Cure Rate Estimation